ASCO is pleased to welcome the 2016- 2017 ASCO Board of Directors and introduce seven newly instated leaders, who began their terms at the conclusion of the Annual Business Meeting during the 2016 ASCO Annual Meeting in Chicago. Read more about the Board of Directors on ASCO.org.

Major priorities for the incoming Board will be the launch of Targeted Agent and Profiling Utilization Registry (TAPUR) Study; the development of CancerLinQ™ and other ASCO efforts to improve quality and value in cancer care; addressing the global burden of cancer, particularly in areas with the most limited resources; advocating for the economics of oncology practice and health care payment reform; providing continued support of crucial medical research; and engaging every member of ASCO at each stage of their career.

Board Officers

2016-2017 President—Daniel F. Hayes, MD, FASCO, is a Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center.

President-Elect—Bruce E. Johnson, MD, FASCO, is Chief Clinical Research Officer and Institute Physician at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is the Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program.

Immediate Past President—Julie M. Vose, MD, MBA, FASCO, is the Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology/ Hematology Division in the Department of Internal Medicine at the University of Nebraska Medical Center. She is the Associate Director of Clinical Research at the Fred and Pamela Buffett Cancer Center.

Treasurer—Craig R. Nichols, MD, is the Co-Director of the Testicular Cancer Multidisciplinary Clinic at Virginia Mason Medical Center in Seattle. He serves as co-primary investigator on the recently funded Northwest National Cancer Institute Community Oncology Research Program. Dr. Nichols is the Executive Officer of Cancer Control and Prevention Research for the Southwest Oncology Group.

Board Members

Pediatric Oncologist—Peter C. Adamson, MD, is Chair of the Children’s Oncology Group, President of the Children’s Oncology Group Foundation, and a Professor of Pediatrics and Pharmacology at The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania.

Undesignated Specialist—Charles D. Blanke, MD, FACP, FASCO, is a Professor of Medicine in the Division of Hematology and Medical Oncology at Oregon Health and Science University’s Knight Cancer Institute.

Community Oncologist—Linda Bosserman, MD, FACP, is an Assistant Clinical Professor and staff physician at City of Hope.

Radiation Oncologist—Walter J. Curran Jr., MD, FACR, is the Executive Director of the Winship Cancer Institute of Emory University, the Lawrence W. Davis Professor and Chair of Emory’s Department of Radiation Oncology, and the Associate Vice President for Cancer at the Woodruff Health Sciences Center.

Undesignated Specialist—Stephen B. Edge, MD, FACS, FASCO, is the Director of the Baptist Cancer Center and an Adjunct Professor of Surgery at the Vanderbilt University School of Medicine.

Undesignated Specialist—Paulo M. G. Hoff, MD, PhD, FACP, is a Professor of Oncology and General Director of the Instituto do Câncer do Estado de São Paulo (ICESP), at the University of São Paulo, and General Director of the Oncology Center at the Hospital Sírio Libanês, Brazil.

Undesignated Specialist—Arti Hurria, MD, is Director of the Cancer and Aging Research Program, Co-Leader of the Cancer Control and Population Sciences Program, and Associate Professor of Medical Oncology and Therapeutics Research at City of Hope.

Undesignated Specialist—Maha Hussain, MD, FACP, FASCO, is the Cis-Maisel Professor of Oncology, and Professor of Medicine and Urology at the University of Michigan Comprehensive Cancer Center (UMCCC). Dr. Hussain has also served as the Associate Director for Clinical Research and Co-Leader of the Prostate Cancer/Genitourinary Oncology Program, as well as the Associate Chief for Clinical Research in the Division of Hematology/Oncology at UMCCC.

International Oncologist—David Khayat, MD, PhD, FASCO, is the Head of the Department of Medical Oncology at Pitié-Salpêtrière Hospital, Paris, France.

Medical Oncologist—Neal J. Meropol, MD, FASCO, is a Professor of Medicine and Chief of the Division of Hematology and Oncology at University Hospitals Case Medical Center & Case Western Reserve University, Associate Director for Clinical Research at Case Comprehensive Cancer Center, Associate Director for Clinical Programs at University Hospitals Seidman Cancer Center, and the Dr. Lester E. Coleman, Jr., Endowed Chair in Cancer Research and Therapeutics.

Community Oncologist—Therese M. Mulvey, MD, FASCO, is the Director of Breast Oncology at the Massachusetts General Hospital/North- Shore Cancer Center and Assistant Professor of Medicine at Harvard Medical School.

Community Oncologist—J. Chris Nunnink, MD, FASCO, is an Attending Physician in Medical Oncology at the University of Vermont Medical Center and an Associate Professor at the Vermont Cancer Center and the College of Medicine at the University of Vermont.

Conquer Cancer Foundation Board of Directors Chair—Thomas G. Roberts Jr., MD, is a Managing Member of Farallon Capital Management, LLC, and previously served as an attending oncologist at Massachusetts General Hospital, an instructor of medicine at Harvard Medical School, and a visiting scientist at the Massachusetts Institute of Technology.

International Oncologist—Jaap Verweij, MD, PhD, is a medical oncologist and currently Dean of the Faculty of Medicine at Erasmus University and Vice-Chair of the Board of Directors at Erasmus Medical Center.

Undesignated Specialist—Jedd D. Wolchok, MD, PhD, is Chief of the Melanoma and Immunotherapeutics Service in the Department of Medicine and the Associate Director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.

2016-2017 ASCO Committee Chairs

Incoming ASCO committee members also began their terms during the 2016 Annual Business Meeting. Read more about ASCO committees on ASCO.org. They are led by the following Chairs:

• Bylaws—Michael P. Link, MD, FASCO
• Cancer Communications—Harold J. Burstein, MD, PhD, FASCO
• Cancer Education—Michael A. Thompson, MD, PhD
• Cancer Prevention—Karen H. Lu, MD
• Cancer Research—Apostolia Maria Tsimberidou, MD, PhD
• Cancer Survivorship—Deborah Mayer, PhD, AOCN, ANP-BC
• Conquer Cancer Foundation Grants Selection—Christina M. Annunziata, MD, PhD
• Clinical Practice—Debra A. Patt, MD, MPH, MBA
• Clinical Practice Guidelines—Neelima Denduluri, MD
• Ethics—Nneka Obiajulu Sederstrom, PhD, FCCP, MA, MPH
• Government Relations—Blase N. Polite, MD, MPP
• Health Disparities—Karen Marie Winkfield, MD, PhD
• International Affairs—Alexandru E. Eniu, MD, PhD
• Membership—Edgardo S. Santos, MD
• Nominating—David Spriggs, MD
• Professional Development—Suresh S. Ramalingam, MD
• Quality of Care—Arif Kamal, MD, MHS, FAAHPM
• State Affiliate Council—Tracey Weisberg, MD
• Scientific Program—David C. Smith, MD
• Special Awards Selection—Julie M. Vose, MD, MBA, FASCO
• Workforce Advisory Group—Stephanie F. Williams, MD, FACP